Clinical Trial: Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695740) titled 'Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma' on July 06.

Brief Summary: The goal of this Phase 2 clinical trial is to learn whether YKST02 is effective and safe in adults with relapsed or refractory multiple myeloma. The study will also evaluate how YKST02 is processed by the body (pharmacokinetics), how it affects the body (pharmacodynamics), and whether it causes the body to produce anti-drug antibodies.

The main questions it aims to answer are:

Does YKST02 demonstrate clinical efficacy in adults with relapsed or refractory multiple myeloma? What side effects occur during treatment with YKST02? What ar...